News | August 08, 2024
Balaji Amines Q4 FY25 revenue stood at Rs. 393 Cr
The pharma market is showing encouraging signs of improvement, positioning us well for future growth
The pharma market is showing encouraging signs of improvement, positioning us well for future growth
Organization to provide vaccinations & treatments for several monsoon related diseases and illnesses across all 102 clinics
Both departments will be equipped with specialized professionals and state-of-the-art facilities ensuring the highest standards of care
Pharmaceuticals and Consumer Health report higher sales (Fx & portfolio adj.) and lower earnings
The drugmaker's net profit slipped 26 per cent on-year to Rs 143.8 crore
To co-develop and co-commercialize MK-6070, an investigational delta-like ligand 3 (DLL3) targeting T-cell engager, worldwide except for Japan where Merck retains exclusive rights
Observes no adverse impact of non-nutritive sweetener (NNS) - sucralose on glycemic markers
The successful completion of the global Phase 3 trials paves the way to obtain marketing approval in the U.S. and EU
Being the first approved applicant, Lupin is eligible for 180 days of CGT exclusivity
Indraprastha Medical Corporation has reported total income of Rs. 352.98 crores during the quarter ended June 30, 2024
Subscribe To Our Newsletter & Stay Updated
